Pieter Dorrestein: Small molecules, big goals

Credit: © Max Dolberg" /> Credit: © Max Dolberg Pieter Dorrestein went to Northern Arizona University primarily for the rocks. The rocky landscape made it the obvious choice for an aspiring geologist, and the rock climbing was just as appealing. In 1997, as a sophomore, Dorrestein heard that chemist John MacDonald was looking for a climbing partner. Once they'd paired up, the two hit it off and Dorrestein became fascinated with MacDonald's work in molecula

Written byAndrea Gawrylewski
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Pieter Dorrestein went to Northern Arizona University primarily for the rocks. The rocky landscape made it the obvious choice for an aspiring geologist, and the rock climbing was just as appealing. In 1997, as a sophomore, Dorrestein heard that chemist John MacDonald was looking for a climbing partner. Once they'd paired up, the two hit it off and Dorrestein became fascinated with MacDonald's work in molecular crystal structure. He joined MacDonald's lab that same year.

I got so fascinated by these large molecular structures — not just small molecule crystallography, but large molecule crystallography," Dorrestein says. "So I started reading papers on crystal structure."

In 1998, Dorrestein began graduate work at Cornell University, with the intention of building small molecules that interact with proteins. However, he soon switched into Tadhg Begley's lab, which was concentrating on vitamin biosynthesis â?? a process that also involves small molecular interactions, but with a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies